Neurocrine Biosciences (NBIX) Misses Q4 EPS by 11c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $156.71 -1.04%
Revenue Growth %: +30.8%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: +30.8%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.07, $0.11 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $94.52 million versus the consensus estimate of $87.77 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
